NCT01282762View on ClinicalTrials.gov

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

CompletedOBSERVATIONAL
Enrollment

147

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Chronic Kidney Disease
Interventions
BIOLOGICAL

HEPLISAV

"0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.~HEPLISAV booster injection = one dose of 0.5 mL volume when needed."

BIOLOGICAL

Engerix-B

"2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.~Engerix-B booster injection = one dose of 2.0 mL volume when needed"

Trial Locations (1)

23507

Clinical Research Associates of Tidewater, Norfolk

Sponsors
All Listed Sponsors
lead

Dynavax Technologies Corporation

INDUSTRY

NCT01282762 - Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter